TIL Technology

Publication and Scientific Presentations

2019

Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Seth Wardell1, Maritza Lienlaf-Moreno1, Michelle Blaskovich1, Ian Frank1, Virginia Van Grod1, Maria Fardis1 and Joseph Wypych1

1Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA

Safety and efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Amod Sarnaik, MD1, Nikhil I. Khushalani, MD1,Jason Alan Chesney, MD, PhD2, Harriet M. Kluger, MD3, Brendan D. Curti, MD4, Karl D. Lewis, MD5, Theresa Medina, MD5, Sajeve Samuel Thomas, MD6,  Anna C. Pavlick, MD, MBA7, Eric D. Whitman, MD8, Salvador Algarra9, Pippa Corrie, PhD, BMBCh, FRCP 10, Omid Hamid, MD11, Jose Lutzky, MD12, Judit Oláh, MD, DSc13, Jeffrey S. Weber, MD, PhD7, James M. G. Larkin, MD, PhD14, Wen Shi, MD, PhD15, Kelly DiTrapani, RN, BSN, BA15, Harry Qin, PhD15, Mariam Mirgoli15, Renee Wu, PhD15, Toshimi Takamura, BS15, Maria Fardis, PhD, MBA15, John M. Kirkwood, MD16

1H. Lee Moffitt Cancer Center, Tampa, FL, USA; 2James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; 3Yale University School of Medicine, Smilow Cancer Center, New Haven Hospital, New Haven, CT, USA; 4Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA; 5University of Colorado Cancer Center – Anschutz Medical Campus , Aurora, CO, USA; 6University of Florida Health Cancer Center at Orlando Health, Orlando, FL, USA; 7Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA; 8Atlantic Health System Cancer Care, Morristown, NJ, USA; 9Clínica Universidad de Navarra, Pamplona, Spain; 10Cambridge University Hospitals NHS Foundation Trust – Addenbrooke’s Hospital, Cambridge, UK; 11The Angeles Clinic and Research Institute, Los Angeles, CA, USA; 12Mount Sinai Comprehensive Cancer Center, Miami, FL, USA; 13University of Szeged – Albert Szent-Györgyi Health Center, Szegedi, Hungary; 14Royal Marsden NHS Foundation Trust, London, UK; 15Iovance Biotherapeutics, Inc. San Carlos, CA, USA; 16Hillman Cancer Center – University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Michelle R. Simpson-Abelson1, Angel Hilton1, Kenneth D’Arigo1, Maria Fardis1, and Cécile Chartier1

1Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA

Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD

Inbar Azoulay Alfaguter1, Michelle Simpson-Abelson1, Krit Ritthipichai1, Kenneth D’Arigo1, Florangel Hilton1, Marcus Machin1, Dingxue Yan2, James Cardia2, Maria Fardis1, and Cécile Chartier

1Iovance Biotherapeutics, Inc. Tampa, FL and San Carlos, CA, USA; 2Phio Pharmaceuticals Marlborough, MA, USA

Iovance Peripheral Blood Lymphocytes (PBL): A Potential Cell Therapy Strategy For The Treatment of Chronic Lymphocytic Leukemia PDF Poster | European Hematologic Association Annual Congress – June 13-16, 2019 | Amsterdam

Lavakumar Karyampudi1, Michelle Blaskovich*1, Ian Frank*1, Nermin Gerges1, Amanda Stramer1, Arvind Natarajan1, Meixiao Long2, Cecile Chartier1, John Byrd2, Maria Fardis1

1Iovance Biotherapeutics, Inc., San Carlos, CA, USA; 2The Ohio State University, Columbus, OH, USA. *Authors contributed equally to this work.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1 PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Amod Sarnaik1, Nikhil I. Khushalani1, Jason Alan Chesney2, Harriet M. Kluger3, Brendan D. Curti4, Karl D. Lewis5, Sajeve Samuel Thomas6, Eric D. Whitman7, Omid Hamid8, Jose Lutzky9, Anna C. Pavlick10, Jeffrey S. Weber10, James M.G. Larkin11, Debora Barton12, Kelly DiTrapani12, Renee Wu12, Maria Fardis12, John M. Kirkwood13

1H. Lee Moffitt Cancer Center, Tampa, FL; 2James Graham Brown Cancer Center, University of Louisville, Louisville, KY;  3Yale School of Medicine, New Haven, CT; 4Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR; 5University of Colorado Comprehensive Cancer Center, Aurora, CO; 6University of Florida Health Cancer Center at Orlando Health, Orlando, FL; 7Atlantic Health System Cancer Care, Morristown, NJ;  8The Angeles Clinic and Research Institute, Los Angeles, CA; 9Mount Sinai Comprehensive Cancer Center, Miami, FL; 10Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; 11Royal Marsden NHS Foundation Trust, London, United Kingdom; 12Iovance Biotherapeutics, Inc., San Carlos, CA; 13Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

Safety & efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Amir A. Jazaeri1, Emese Zsiros2, Rodabe Navroze Amaria1, Andrew S. Artz3, Robert P. Edwards4, Robert Michael Wenham5, Brian M. Slomovitz6, Axel Walther7, Sajeve Samuel Thomas8, Jason Alan Chesney9, Robert Morris10, Koji Matsuo11, Stephanie Gaillard12, Peter G. Rose13, Jesus Garcia Donas14, Jacqueline Maria Tromp15, Kelly DiTrapani16, Huiling Li16, Maria Fardis16, Bradley J. Monk17

1The University of Texas – MD Anderson Cancer Center, Houston, TX; 2Roswel Park Cancer Institute, Buffalo, NY; 3University of Chicago Comprehensive Cancer Center, Chicago, IL; 4Hillman Cancer Institute University of Pittsburgh Medical Center, Pittsburgh, PA; 5H. Lee Moffitt Cancer Center, Tampa, FL; 6Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; 7University Hospitals Bristol, Bristol, United Kingdom; 8University of Florida Health Cancer Center at Orlando Health, Orlando, FL; 9James Graham Brown Cancer Center, University of Louisville, Louisville, KY; 10Barbara A. Karmanos Cancer Center, Wayne State University, Detroit, MI; 11Los Angeles County Hospital-University of Southern California, Los Angeles, CA; 12Johns Hopkins School of Medicine, Baltimore, MD; 13Cleveland Clinic Foundation, Cleveland, OH; 14Hospital Universitario Madrid Sanchinarro, Madrid, Spain; 15Academical Medical Center, Amsterdam, Netherlands; 16Iovance Biotherapeutics, Inc., San Carlos, CA; 17University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ

A Phase 2 study of autologous tumor infiltrating lymphocytes (TIL; lifileucel [LN-144]/LN-145) in patients with solid tumors PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago

Jason Chesney1, Jose Lutzky2, Sajeve Samuel Thomas3, Jorge Nieva4, Eva Muñoz Couselo5, Juan Francisco Moreno Rodriguez6, Juan Jesus Martin-Liberal7, Alex Cacovean8, Huiling Li8, Zelanna Goldberg8, Maria Fardis8, Scott Gettinger9

1James Graham Brown Cancer Center, Louisville, KY; 2Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; 3University of Florida Health Cancer Center, Orlando, FL; 4USC Norris Cancer Center, Los Angeles, CA; 5Hospital Universitario Vall d’Hebron – PPDS, Barcelona, ES; 6Hospital Universitario HM Sanchinarro – CIOCC, Madrid, ES; 7ICO l’Hospitalet – Hospital Duran i Reynals, Barcelona, ES; 13Iovance Biotherapeutics, San Carlos, CA; 9Yale Cancer Center, New Haven, CT

Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from bladder cancer for adoptive immunotherapy PDF Poster | AACR Meeting – Bladder Cancer: Transforming the Field, May 18-21, 2019 | Denver

Qiang John Li, Khurshid Guru, Amit Lugade, Elizabeth Brese, Kunle Odunsi, Anand Veerapathran, Kenneth Onimus, Adrian Wells, Cécile Chartier, Arvind Natarajan, Maria Fardis, Gurkamal Chatta

Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma PDF Poster | AACR Annual Meeting,  March 29-April 03, 2019 | Atlanta

Viktoria Gontcharova, Sam Suzuki, Michelle Abelson, Michelle Blaskovich, Cécile Chartier

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors PDF Poster | ASCO-SITC Clinical Immuno-Oncology Symposium,  February 28-March 02, 2019 | San Francisco

Amod Sarnaik1, Sajeve Samuel Thomas2, Diwakar Davar3, John M. Kirkwood3, Harriet Kluger4, Jose Lutzky5, Melissa Wilson6, Anna C. Pavlick7, Brendan Curti8, Eric Whitman9, Karl Lewis10, Giao Phan11, Omid Hamid12, Evidio Domingo-Musibay13, Marc Ernstoff14, Hendrik-Tobias Arkenau15, Judit Olah16, Pippa Corrie17, Stéphane Dalle18, Salvador Algarra19, Gregory Daniels20, Lavakumar Karyampudi21, Toshimi Takamura21, Debora Barton21, Sam Suzuki21, Nancy L. Samberg21, Maria Fardis21, Jason Chesney22


2018

 

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors PDF Poster | SITC Annual Meeting,  November 9-11, 2018 | Washington, DC

Amod Sarnaik1, Sajeve Samuel Thomas2, Diwakar Davar3, John M. Kirkwood3, Harriet Kluger4, Jose Lutzky5, Melissa Wilson6, Anna C. Pavlick7, Brendan Curti8, Eric Whitman9, Karl Lewis10, Giao Phan11, Omid Hamid12, Evidio Domingo-Musibay13, Marc Ernstoff14, Hendrik-Tobias Arkenau15, Judit Olah16, Pippa Corrie17, Stéphane Dalle18, Salvador Algarra19, Gregory Daniels20, Lavakumar Karyampudi21, Toshimi Takamura21, Debora Barton21, Sam Suzuki21, Nancy L. Samberg21, Maria Fardis21, Jason Chesney22

 1Moffitt Cancer Center, Tampa, FL, USA; 2Univ. of Florida Health Cancer Center, Orlando, FL, USA; 3Univ. of Pittsburgh-Hillman Cancer Center, Pittsburgh, PA, USA 4Yale Cancer Center, New Haven, CT, USA; 5Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA; 6Thomas Jefferson Kimmel Cancer Center, Philadelphia, PA, USA; 7NYU Perlmutter Cancer Center-Langone, New York, NY, USA; 8Earle A. Chiles Research Institute-Providence Cancer Center, Portland, OR, USA; 9Atlantic Health System Cancer Care, Morristown, NJ, USA; 10Univ. of Colorado Health Cancer Care-Anschutz Medical Campus; Aurora, CO, USA; 11Virginia Commonwealth University-School of Medicine, Richmond, VA, USA; 12 The Angeles Clinic, Los Angeles, CA, USA; 13Univ. of Minnesota Health-Masonic Cancer Center, Minneapolis, MN, USA 14 Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 15Sarah Cannon Research Institute, London, UK 16Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ, Csongrad, HU; 17Addenbrooke’s Hospital, Cambridge, UK; 18Centre Hospitalier Lyon Sud, Rhone-Alpes, FR; 19Clínica Universidad de Navarra, Pamplona, Navarra, ES; 20University of California San Diego-Moores Cancer Center, San Diego, CA, USA; 21Iovance Biotherapeutics, San Carlos, CA, USA; 22James Graham Brown Cancer Center

PD1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy PDF Poster | SITC Annual Meeting,  November 9-11, 2018 | Washington, DC

Michelle R. Simpson-Abelson, Kenneth D’Arigo, Angel Cedano-Hilton, Ian Frank, Viktoria Gontcharova, Krit Ritthipichai, and Cécile Chartier

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Abstract TPS9595 and poster number 422a – poster presented Monday, June 4th
Amod Sarnaik1, Brendan Curti2, Diwakar Davar3, John M. Kirkwood3, Omid Hamid4, Jose Lutzky5, Melissa Wilson6, Harriet Kluger7, Eric Whitman8 , Giao Phan9, Sajeve Samuel Thomas10,Karl Lewis11, Hendrik-Tobias Arkenau12, Bente Larsen13, Igor Gorbatchevsky13, Corina Andresen13,  Sam Suzuki13, Nancy Samberg13, Maria Fardis13, Jason Chesney14 1Moffitt Cancer Center, Tampa, FL; 2Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR; 3University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 4The Angeles Clinic and Research Institute, Los Angeles, CA; 5Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; 6New York University – Perlmutter Cancer Center – Langone Medical Center, New York, NY; 7Yale Cancer Center, New Haven, CT; 8 Atlantic Health System Cancer Care, Morristown, NJ; 9Virginia Commonwealth University, Richmond, VA; 10University of Florida Health Cancer Center, Orlando, FL; 11University of Colorado Cancer Center, Denver CO; 12Sarah Cannon Research Institute London UK; 13Iovance Biotherapeutics, San Carlos, CA; 14James Graham Brown Cancer Center, Louisville, KY

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Abstract TPS6096 and poster number 81a – poster presented Saturday, June 2nd 
Rom Leidner1, Ammar Sukari2, Christine Chung3, James Ohr4, Missak Haigentz5, Ezra E. W. Cohen6, Robert J. Brown7, Igor Gorbatchevsky7, Sam Suzuki7, Maria Fardis7, Robert L. Ferris4 1Earle A. Chiles Research Institute – Providence Cancer Center, Portland, OR;  2Barbara Ann Karmanos Cancer Institute, Detroit, MI;  3Moffitt Cancer Center, Tampa, FL;  4University of Pittsburgh Medical Center, Pittsburgh, PA; 5Morristown Medical Center/Atlantic Health System, Morristown, NJ; 6University of California, San Diego, CA; 7Iovance Biotherapeutics, San Carlos, CA

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma 
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Amir Jazaeri1, Robert Edwards2, Robert Wenham3, Koji Matsuo4, Gini F. Fleming5, David M. O’Malley6, Brian Slomovitz7, Bradley Monk8, Robert J. Brown9, Igor Gorbatchevsky9, Sam Suzuki9, Maria Fardis9, Emese Zsiros10  1MD Anderson Cancer Center, Houston, TX; 2University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 3Moffitt Cancer Center, Tampa, FL; 4Norris Cancer Center, University of Southern California, Los Angeles, CA; 5University of Chicago, Chicago, IL; 6The James Cancer Center, Ohio State University, Columbus, OH; 7Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; 8Arizona Oncology, University of Arizona College of Medicine, and Phoenix Creighton University School of medicine at St. Joseph’s Hospital, Phoenix, AZ;  9Iovance Biotherapeutics, San Carlos, CA; 10Roswell Park Cancer Institute, Pittsburgh, PA

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | ASCO ANNUAL MEETING, JUNE 1-5, 2018 | CHICAGO
Sylvia Lee1, Liza Villaruz2, Susie Tanamly3, Igor Gorbatchevsky3, Corina Andresen3,  Sam Suzuki3, Maria Fardis3, Missak Haigentz4   1University of Washington, Seattle, WA; 2University of Pittsburgh Medical Center – Hillman Cancer Center, Pittsburgh, PA; 3Iovance Biotherapeutics, San Carlos, CA; 4Atlantic Health System/Morristown Medical Center, Morristown, NJ

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Amod Sarnaik1, Brendan Curti2, Diwakar Davar3, Omid Hamid4, Jose Lutzky5, Melissa Wilson6, Harriet Kluger7, Jason Chesney8, Kevin Kim9, Giao Phan10, Sajeve Thomas11, Igor Gorbatchevsky12, Bente Larsen12, Sam Suzuki12, Nancy Samberg12, Maria Fardis12, John M. Kirkwood3

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Rom Leidner1, Ammar Sukari2, Christine Chung3, James Ohr4, Missak Haigentz5, Ezra E. W. Cohen6, Robert J. Brown7, Igor Gorbatchevsky7, Sam Suzuki7, Maria Fardis7, Robert L. Ferris4

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Amir Jazaeri1, Robert Edwards2, Robert Wenham3, Koji Matsuo4, Gini F. Fleming5, David M. O’Malley6, Brian Slomovitz7, Bradley Monk8, Robert J. Brown9, Igor Gorbatchevsky9, Sam Suzuki9, Maria Fardis9, Emese Zsiros10

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Sylvia Lee1, Liza Villaruz2, Susie Tanamly3, Igor Gorbatchevsky3, Sam Suzuki3, Maria Fardis3, Missak Haigentz4

Anti-OX40 Agonistic Antibody Enhances ex vivo CD8+ TIL Expansion with Increased T-cell Effector Function
PDF Poster | AACR ANNUAL MEETING, APRIL 14-18, 2018 | CHICAGO
Krit Ritthipichai, Marcus Machin, Maria Fardis, and Cecile Chartier


2017

Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Amod Sarnaik1, Jason Chesney2, Harriet Kluger3, Brendan Curti4, Omid Hamid5, Jose Lutzky6, Maria Fardis7, Igor Gorbatchevsky7, Sam Suzuki7, Bente Larsen7, Nancy L. Samberg7, John Kirkwood8

A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Seth Wardell, Ian Frank, Lavakumar Karyampudi, Anand Veerapathran, Michelle Simpson-Abelson, Maritza Lienlaf Moreno, Michelle Blaskovich, Joseph Wypych, and Maria Fardis

Studies of Key Quality Attributes for TIL Product, LN-144
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Krit Ritthipichai, Ian Frank, Marcus Machin, Michelle Blaskovich, Amanda Stramer, Michelle Simpson-Abelson, Maria Fardis, Cecile Chartier

A phase 2 study to evaluate the safety and efficacy of using of using autologous tumor infiltrating lymphocytes (LN -145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Leidner R1, Ohr J2, Chung C3, Brown RJ4, Suzuki S4, Gorbatchevsky I4, Fardis M4, and Ferris RL2

A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Amir Jazaeri1, Robert Edwards2, Emese Zsiros3, Robert Brown4, Igor Gorbatchevsky4, Sam Suzuki4, Maria Fardis4, Robert Wenham5

The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
PDF Poster | SITC ANNUAL MEETING, NOVEMBER 8 2017 | NATIONAL HARBOR, MD
Michelle R. Simpson-Abelson, Christopher Mosychuk, Ian Frank, Krit Ritthipichai, and Cecile Chartier

Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors – Implications for the Development of Novel Therapies for Lymphoma
PDF Poster | ESMO Annual Meeting, September 7-12, 2017 | Madrid
Lavakumar Karyampudi, Aishwarya Gokuladass, Michelle Blaskovich, Maria Fardis, Michael T Lotze

TIL Candidate Shows Potential in Metastatic Melanoma Based on Interim Data
News Feature | Drug Discovery & Development, 06/23/2017

Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-Treated Metastatic Melanoma Patients Following Checkpoint Therapy
PDF Poster | ASCO Annual Meeting 2017
Amod Sarnaik, Harriet Kluger, Jason Chesney, Jyothi Sethuraman, Michael T. Lotze, Bente Larsen, Igor Gorbatchevsky, Nancy L. Samberg, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan Curti

K+ Channel Activation Promotes Tumor Infiltrating Lymphocyte (TIL) Expansion and Enhances Expression of CCR7
PDF Poster | AAI Annual Meeting 2017
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, and Michael T. Lotze

Emigrant Tumor Infiltrating Lymphocytes Profoundly Differ from Remnant T cells
PDF Poster | AACR Annual Meeting 2017
Michelle R. Simpson-Abelson, Christopher Mosychuk, Maria Fardis, and Michael T. Lotze


2016

P14 Bioluminescent redirected lysis assay (BRLA) as an efficient potency assay to assess tumor-infiltrating lymphocytes (TILs) for immunotherapy
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Aishwarya Gokuldass, Michelle A Blaskovich, Charlene Kopits, Brian Rabinovich, Michael T. Lotze

P11 Stable tumor-infiltrating lymphocytes (TIL) phenotype following cryopreservation
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Ian Frank, Amanda Stramer, Michelle A Blaskovich, Seth Wardell, Maria Fardis, James Bender, Michael T Lotze

P41 Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Jyothi Sethuraman, Laurelis Santiago, Jie Qing Chen, Zhimin Dai, Seth Wardell, James Bender, Michael T Lotze

P46 Artificial antigen presenting cells promote expansion of tumor infiltrating lymphocytes (TILs)
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Anandaraman Veerapathran, Aishwarya Gokuldass, Amanda Stramer, Jyothi Sethuraman, Michelle A Blaskovich, Doris Wiener, Ian Frank, Laurelis Santiago, Brian Rabinovich, Maria Fardis, James Bender, Michael T Lotze

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
PubMed | Journal of Clinical Oncology 2016 34:20, 2389-2397, doi: 10.1200/JCO.2016.66.7220
Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong MLM, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, and Rosenberg SA


2015

Adoptive cell transfer as personalized immunotherapy for human cancer
Science | Science 03 Apr 2015, Vol. 348, Issue 6230, pp. 62-68, DOI 10.1126/science.aaa4967
Rosenberg SA, and Restifo NP

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
PubMed | Clin Cancer Res. 2015;21(3):611-21
Chacon JA, Sarnaik AA, Chen JQ, et al.


2014

Finding suitable targets is the major obstacle to cancer gene therapy
Nature | Cancer Gene Ther. 2014;21(2):45-7
Rosenberg SA

Exploiting the curative potential of adoptive T-cell therapy for cancer
PubMed | Immunol Rev. 2014;257(1):56-71
Hinrichs CS, Rosenberg SA